A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · see citing works

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279 · see citing works

The Discovery and Development of Liraglutide and Semaglutide

Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · see citing works

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · see citing works

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 503 · see citing works

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · see citing works

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

Shiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263 · see citing works

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · see citing works

Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling

Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217 · see citing works

A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis

Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149 · see citing works

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE ^−/− mouse model

Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148 · see citing works

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143 · see citing works

Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner

Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137 · see citing works

Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes

Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.004 · Cited by 132 · see citing works

Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism

Giagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109 · see citing works

Alleviation of depression by glucagon-like peptide 1 through the regulation of Neuroinflammation, neurotransmitters, neurogenesis, and synaptic function

Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109 · see citing works

Glucagon-like Peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation

Xiao-Yun, X., Zhao-Hui, M., Ke, C., Hong-Hui, H., & Yan-Hong, X. (2011) · Medical Science Monitor · doi:10.12659/msm.881383 · Cited by 88 · see citing works

PAI-1 and diabetes: a journey from the bench to the bedside

Schneider, D. J., & Sobel, B. E. (2012) · Diabetes Care · doi:10.2337/dc12-0638 · Cited by 78 · see citing works

Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice

GOU, S., ZHU, T., WANG, W., XIAO, M., WANG, X.-C., & CHEN, Z.-H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.010 · Cited by 66 · see citing works

Using a Reporter Mouse to Map Known and Novel Sites of GLP-1 Receptor Expression in Peripheral Tissues of Male Mice

Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54 · see citing works

Direct cardiovascular effects of glucagon like peptide-1

Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45 · see citing works

Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control

Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44 · see citing works

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Endocrine Connections · doi:10.1530/ec-16-0113 · Cited by 44 · see citing works

Selective targeting of glucagon‐like peptide‐1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes

Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33 · see citing works

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17 · see citing works

Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis

Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18 · see citing works

Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity

Wang, G., Wu, P., Qiu, Y., Dong, X., Wang, Y., Chi, Y., Zhang, F., Li, Y., Zhang, J., Huang, Z., et al. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000388 · Cited by 17 · see citing works